Key facts
- It has raised $10.4M; the latest was Seed Round ($10.4M) in Dec 2025.
- Notable investors include Qiming Venture Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Convergen
- ·The full record, as it builds
Funding rounds
No funding rounds for Convergen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Convergen
Provider of scientific research and laboratory services intended to break the fragmentation of data in drug discoveries. The company's services help in the systematic search for translatable science to improve the efficiency of identifying innovative opportunities and coordinate diverse modules to fit the needs of different projects, enabling researchers to meet the unmet clinical needs and enhance the life quality of patients.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- convergenbio.com/
- Ownership
- Privately Held (backing)
Convergen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Convergen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Convergen in its N-PORT filings yet. We sweep new filings monthly.